Stability Engineering Of Human Antibody Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$421,104.00
Summary
Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pha ....Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pharmaceutical company.Read moreRead less
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Monoclonal antibodies, such as the cancer therapeutic Pembrolizumab, have revolutionised the treatment of cancer and many inflammatory conditions. With over $100 billion in sales in 2018, they also underpin a growing biotech industry. We have developed a highly specific, high affinity therapeutic antibody candidate, and demonstrated efficacy in animal models of malignancy. This project will advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Development Of A Safer New Treatment For Systemic Lupus Erythematosus That Preserves B Cell Immunity
Funder
National Health and Medical Research Council
Funding Amount
$672,008.00
Summary
Lupus is an illness characterized by the body’s immune system attacking the body itself. More than 5 millions of people worldwide suffer from lupus, in particular Indigenous Australians who are 4 times more likely to develop lupus. Current treatments are toxic and/or lack efficacy. In this proposal we use strong new evidence from the laboratory to support the design of a much safer and more effective treatment for lupus that will be validated for future use in patients.
Development Of Stable Human Antibody Phage Display Libraries
Funder
National Health and Medical Research Council
Funding Amount
$539,644.00
Summary
Antibodies are blockbuster therapeutics for the treatment of cancer and inflammation. Unfortunately, they often display limited stability which greatly hinders development and production. This project focuses on the construction of large libraries of stable antibodies, thereby streamlining the development of new therapeutics.
Cancer is now the number one killer of Australians and there is an unmet medical need to develop new therapies that are safe and maximize anti-cancer efficacy. Cancer immunotherapy now represents a new fourth pillar in cancer treatment to complement surgery, radiotherapy and chemo-/targeted therapies. This application aims to develop new therapeutic approaches to broaden the effectiveness of cancer immunotherapy and potentially allow the treatment of a broader range of cancers and patients.
Development Of A Humanised Antibody To MIC-1/GDF15 For Therapy Of Anorexia/cachexia Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$587,349.00
Summary
Severe starvation and weight loss (cachexia) is a complication that affects about one quarter of cancer patients. In many this is due to the cancer producing a powerfula appetite suppressive protein called MIC-1/GDF15. This weight loss can be prevented by blocking the protein with an antibody drug. We have already shown that we can treat mice in this way by using a mouse antibody. We now aim to engineer these antibodies by making them more human-like. This will allow us to treat weight loss in h ....Severe starvation and weight loss (cachexia) is a complication that affects about one quarter of cancer patients. In many this is due to the cancer producing a powerfula appetite suppressive protein called MIC-1/GDF15. This weight loss can be prevented by blocking the protein with an antibody drug. We have already shown that we can treat mice in this way by using a mouse antibody. We now aim to engineer these antibodies by making them more human-like. This will allow us to treat weight loss in human cancer patients.Read moreRead less
Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.